Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06305728 · ClinicalTrials.gov registry record

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

A clinical trial of Pancreatic Cyst, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
25
Enrollment target
8
Study locations

NCT06305728 is a study of Pancreatic Cyst that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants, below the 549-participant average among 18 other Pancreatic Cyst trials with a reported enrollment target (95% lower). The trial reports 8 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06305728, a study of Pancreatic Cyst, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
25 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study, researchers will look at whether a combination of the following types of imaging with blood tests can detect PDAC in pancreatic cysts: * The ImmunoPET scan (immune-positron emission tomography scan) with the imaging agent 89Zr-DFO-HuMab-5B1 * The HP MRI scan (hyperpolarized pyruvate magnetic resonance imaging scan)

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST 89Zr-DFO-HuMab-5B1 immunoPET
  • DIAGNOSTIC_TEST HP MRI
  • COMBINATION_PRODUCT Blood assay

Study Locations (8)

New York

  • Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All protocol activites) - New York
  • Weill Cornell Medical Center (Specimen Analysis Only) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2024-03-04
Est. Completion 2030-03-04

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT06305728

The ClinicalTrials.gov registry entry for NCT06305728 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 549-participant average among 18 other Pancreatic Cyst trials with a reported enrollment target (95% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cyst appearing as the primary indexed condition, and to 3 interventions - of which 89Zr-DFO-HuMab-5B1 immunoPET is the first listed.

NCT06305728 reports 8 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06305728 about?

NCT06305728 is a clinical study titled "Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms". The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study,...

What is the current status of trial NCT06305728?

This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2024-03-04. Estimated completion is 2030-03-04.

What conditions does trial NCT06305728 study?

This clinical trial studies the following conditions: Pancreatic Cyst.

What interventions are being tested in trial NCT06305728?

The interventions under investigation include: 89Zr-DFO-HuMab-5B1 immunoPET (DIAGNOSTIC_TEST), HP MRI (DIAGNOSTIC_TEST), Blood assay (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06305728?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06305728 being conducted?

This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cyst

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.